Gaucher’s Disease Pipeline Analysis report covers 10 drugs currently in different phases of development. Gaucher’s Disease is a recessive genetic metabolic disorder where there is an inadequate degradation of a specific lipid known as glucocerebroside leading to the build-up of this specific lipid in the liver, spleen, bone marrow and nervous system which interferes with their normal functioning. Major clinical symptoms include, enlargement of spleen and liver also known as hepatosplenomegaly, anaemia, thrombocytopenia and bone diseases in the form of pain and fractures. Three types of Gaucher’s Disease have been recognised so far where Type 1 is the most common and it does not affect the nervous system. People suffering from Type 1 disorder never have any problem during their lifetime. Whereas, Type 2 and Type 3 affects the nervous system.
The report provides Gaucher’s Disease treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Shire, IQVIA, Sanofi and Amicus Therapeutics, Inc. among others.
By Molecule Type
By Route of Administration
* There may be changes in final report as per data availability.